CDC/IDSA COVID-19 Clinician Call: Antibody Therapy under New EUA

*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 6 NU50CK000477-04-01). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.

These one-hour webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Register for next week here.

Moderator:

• Dana S. Wollins, DrPH, MGC
  Vice President, Clinical Affairs & Practice Guidelines, IDSA

Featured Speakers and Presentations:

• Janet Woodcock, M.D.
  On Detail As Therapeutic Lead
  Operation Warp Speed
  Director, Center for Drug Evaluation & Research, U.S. Food and Drug Administration

• John T. Redd, M.D., MPH, FACP
  Chief Medical Officer
  Office of the Assistant Secretary for Preparedness and Response
  U.S. Department of Health and Human Services